128 related articles for article (PubMed ID: 7647577)
21. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
22. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
23. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
[TBL] [Abstract][Full Text] [Related]
24. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
Franklyn JA; Betteridge J; Holder R; Sheppard MC
Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
[TBL] [Abstract][Full Text] [Related]
25. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
[TBL] [Abstract][Full Text] [Related]
26. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
Diamond T; Nery L; Hales I
J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
[TBL] [Abstract][Full Text] [Related]
27. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
28. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
29. Long-term thyroxine treatment and bone mineral density.
Franklyn JA; Betteridge J; Daykin J; Holder R; Oates GD; Parle JV; Lilley J; Heath DA; Sheppard MC
Lancet; 1992 Jul; 340(8810):9-13. PubMed ID: 1351654
[TBL] [Abstract][Full Text] [Related]
30. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
31. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
[TBL] [Abstract][Full Text] [Related]
32. Bone mineral density and metabolism in children treated with L-thyroxine.
Tümer L; Hasanoğlu A; Cinaz P; Bideci A
J Pediatr Endocrinol Metab; 1999; 12(4):519-23. PubMed ID: 10417967
[TBL] [Abstract][Full Text] [Related]
33. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism.
Lecomte P; Lecureuil N; Osorio-Salazar C; Lecureuil M; Valat C
Thyroid; 1995 Feb; 5(1):19-23. PubMed ID: 7787428
[TBL] [Abstract][Full Text] [Related]
34. Thyroid hormone treatment aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women.
Knudsen N; Faber J; Sierbaek-Nielsen A; Vadstrup S; Sørensen HA; Hegedüs L
J Intern Med; 1998 Feb; 243(2):149-54. PubMed ID: 9566644
[TBL] [Abstract][Full Text] [Related]
35. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade.
Fazio S; Biondi B; Carella C; Sabatini D; Cittadini A; Panza N; Lombardi G; Saccà L
J Clin Endocrinol Metab; 1995 Jul; 80(7):2222-6. PubMed ID: 7608283
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter.
Wesche MF; Tiel-V Buul MM; Lips P; Smits NJ; Wiersinga WM
J Clin Endocrinol Metab; 2001 Mar; 86(3):998-1005. PubMed ID: 11238476
[TBL] [Abstract][Full Text] [Related]
37. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
Kung AW; Yeung SS
J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
[TBL] [Abstract][Full Text] [Related]
38. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
39. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
[TBL] [Abstract][Full Text] [Related]
40. Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin.
Ongphiphadhanakul B; Alex S; Braverman LE; Baran DT
J Bone Miner Res; 1992 Oct; 7(10):1227-31. PubMed ID: 1456090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]